A carregar...
Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
BACKGROUND: Current national estimates for acute myelogenous leukemia (AML) indicate this disease accounts for 1.1% of new cancer diagnoses and 1.8% of cancer deaths in the United States. The 5-year overall survival rate for patients with AML was 27.4% between 2008 and 2014. The standard induction f...
Na minha lista:
| Publicado no: | Am Health Drug Benefits |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Engage Healthcare Communications, LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6306103/ https://ncbi.nlm.nih.gov/pubmed/30647825 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|